Grifols makes medicines derived from human plasma and diagnostic products for hospitals, clinics and laboratories. GRFS reports earnings on Mon, Nov 2, 2026.
Prices, price targets and earnings estimates for GRFS are shown to AI Starter and AI Pro members. Ratings, flow and news are open to everyone.See plansSign in
No whale options trades in GRFS in the last 90 days.
Total alerts
0
Bullish
0
0%
Bearish
0
0%
Date span
—
Loading…
AI Auto Pilots
Paper trading
StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether GRFS is in one of them and how their past GRFS trades turned out.
Members of Congress and senior officials report trades up to 45 days later, as dollar ranges. Filings show a trade happened, not why. Not investment advice.
About Grifols SA
Grifols makes medicines derived from human plasma, the liquid part of blood, and sells them to hospitals, clinics and healthcare providers. These therapies treat conditions such as immune deficiencies, hemophilia and emphysema linked to alpha 1 protein deficiency. The company also makes diagnostic tests and instruments for blood banks and clinical laboratories, along with infusion solutions and nutrition products for hospital use. It is based in New York and runs plasma collection centers to supply its manufacturing.
